Gut Microbial Signatures for Glycemic Responses of GLP-1 Receptor Agonists in Type 2 Diabetic Patients: A Pilot Study
Open accessThe DOI matches its Crossref record; 19 of the 19 references it cites were found in a registry or an index.
Abstract
Backgrounds: Glucagon-like peptide-1 receptor agonist (GLP-1 RA) is probably one of more effective antidiabetic agents in treatment of type 2 diabetes mellitus (T2D). However, the heterogenicity in responses to GLP-1 RA may be potentially related to gut microbiota, although no human evidence has been published. This pilot study aims to identify microbial signatures associated with glycemic responses to GLP-1 RA. Materials and Methods: Microbial compositions of 52 patients with T2D receiving GLP-1 RA were determined by 16S rRNA amplicon sequencing. Bacterial biodiversity was compared between responders versus non-responders. Pearson’s correlation and random forest tree algorithm were used to identify microbial features of glycemic responses in T2D patients and multivariable linear regression models were used to validate clinical relevance. Results: Beta diversity significantly differed between GLP-1 RA responders (n = 34) and non-responders (n = 18) (ADONIS, P = 0.004). The top 17 features associated with glycohemoglobin reduction had a 0.96 diagnostic ability, based on area under the ROC curve: Bacteroides dorei and Roseburia inulinivorans, the two microbes having immunomodulation effects, along with Lachnoclostridium sp. and Butyricicoccus sp., were positively correlated with glycemic reduction; Prevotella copri, the microbe related to insulin resistance, together with Ruminococcaceae sp., Bacteroidales sp., Eubacterium coprostanoligenes sp., Dialister succinatiphilus, Alistipes obesi, Mitsuokella spp., Butyricimonas virosa, Moryella sp., and Lactobacillus mucosae had negative correlation. Furthermore, Bacteroides dorei, Lachnoclostridium sp. and Mitsuokella multacida were significant after adjusting for baseline glycohemoglobin and C-peptide concentrations, two clinical confounders. Conclusions: Unique gut microbial signatures are associated with glycemic responses to GLP-RA treatment and reflect degrees of dysbiosis in T2D patients.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Reproducible, interactive, scalable and extensible microbiome data science using QIIME 2
Bolyen, E., Rideout, J. R., Dillon, M. R., Bokulich, N. A., Abnet, C. C., Al-Ghalith, G. A., Alexander, H., Alm, E. J., Arumugam, M., Asnicar, F., et al. (2019) · Nature Biotechnology · doi:10.1038/s41587-019-0209-9 · Cited by 23,742
Gut Microbiota in Human Adults with Type 2 Diabetes Differs from Non-Diabetic Adults
Larsen, N., Vogensen, F. K., van den Berg, F. W. J., Nielsen, D. S., Andreasen, A. S., Pedersen, B. K., Al-Soud, W. A., Sørensen, S. J., Hansen, L. H., & Jakobsen, M. (2010) · PLoS ONE · doi:10.1371/journal.pone.0009085 · Cited by 2,952 · cited 1×
“To analyze gut microbiota in our T2D cases with mild to moderate gut microbial dysbiosis, Bacteroidetes and Firmicutes were the dominant phyla, similar to healthy populations (41).”
BackgroundThe Firmicutes/Bacteroidetes Ratio: A Relevant Marker of Gut Dysbiosis in Obese Patients?
Magne, F., Gotteland, M., Gauthier, L., Zazueta, A., Pesoa, S., Navarrete, P., & Balamurugan, R. (2020) · Nutrients · doi:10.3390/nu12051474 · Cited by 2,335 · cited 1×
“The Firmicutes/Bacteroidetes ratio and relative abundances of bacterial genera known for association with T2D (Bacteroides, Faecalibacterium, Roseburia, Bifidobacterium, and Akkermansia) were also compared between the two groups (34, 35).”
BackgroundMechanisms of Action and Therapeutic Application of Glucagon-like Peptide-1
Drucker, D. J. (2018) · Cell Metabolism · doi:10.1016/j.cmet.2018.03.001 · Cited by 2,170 · cited 1×
“Glucagon-like peptide-1 receptor agonist (GLP-1 RA) has pleotropic effects on pancreas, brain, and other target organs, acting through systemic or enteric neuroendocrine cell pathways (3).”
BackgroundHuman gut microbes impact host serum metabolome and insulin sensitivity
Pedersen, H. K., Gudmundsdottir, V., Nielsen, H. B., Hyotylainen, T., Nielsen, T., Jensen, B. A. H., Forslund, K., Hildebrand, F., Prifti, E., Falony, G., et al. (2016) · Nature · doi:10.1038/nature18646 · Cited by 2,116 · cited 1×
“Prevotella copri induces insulin resistance by augmenting circulating concentrations of branched-chain amino acids (50).”
BackgroundSparse and Compositionally Robust Inference of Microbial Ecological Networks
Kurtz, Z. D., Müller, C. L., Miraldi, E. R., Littman, D. R., Blaser, M. J., & Bonneau, R. A. (2015) · PLOS Computational Biology · doi:10.1371/journal.pcbi.1004226 · Cited by 1,799 · cited 1×
“R package igraph and SpiecEasi were used for construction of the co-occurrence network with SparCC correlation coef fi cients (37 – 39).”
MethodRisk factors, mortality, and cardiovascular outcomes in patients with type 2 diabetes
Rawshani, A., Rawshani, A., Franzén, S., Sattar, N., Eliasson, B., Svensson, A.-M., Zethelius, B., Miftaraj, M., McGuire, D. K., Rosengren, A., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1800256 · Cited by 1,475 · cited 1×
“Therefore, glycemic control in T2D patients is critical to reduce diabetic complications, cardiovascular consequences, and costs (2).”
Background9. Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes—2020
American Diabetes Association (2020) · Diabetes Care · doi:10.2337/dc20-s009 · Cited by 914
Regional variation limits applications of healthy gut microbiome reference ranges and disease models
He, Y., Wu, W., Zheng, H.-M., Li, P., McDonald, D., Sheng, H.-F., Chen, M.-X., Chen, Z.-H., Ji, G.-Y., Zheng, Z.-D.-X., et al. (2018) · Nature Medicine · doi:10.1038/s41591-018-0164-x · Cited by 894 · cited 2×
“Conversely, a decrease of genera Bacteroides was a major observation associated with T2D (18).”
BackgroundMucosal microbiome dysbiosis in gastric carcinogenesis
Coker, O. O., Dai, Z., Nie, Y., Zhao, G., Cao, L., Nakatsu, G., Wu, W. K., Wong, S. H., Chen, Z., Sung, J. J. Y., et al. (2018) · Gut · doi:10.1136/gutjnl-2017-314281 · Cited by 695
Cited by
GLP-1 and GLP-2 Orchestrate Intestine Integrity, Gut Microbiota, and Immune System Crosstalk
Abdalqadir, N., & Adeli, K. (2022) · Microorganisms · doi:10.3390/microorganisms10102061 · Cited by 119
Effects of GLP-1 Analogues and Agonists on the Gut Microbiota: A Systematic Review
Gofron, K. K., Wasilewski, A., & Małgorzewicz, S. (2025) · Nutrients · doi:10.3390/nu17081303 · Cited by 90
Polyagonists in Type 2 Diabetes Management
Dissanayake, H. A., & Somasundaram, N. P. (2024) · Current Diabetes Reports · doi:10.1007/s11892-023-01530-2 · Cited by 8
Metadata
- Authors
- Tsai, C.-Y., Lu, H.-C., Chou, Y.-H., Liu, P.-Y., Chen, H.-Y., Huang, M.-C., Lin, C.-H., & Tsai, C.-N.
- Venue
- Frontiers in Endocrinology
- Publisher
- Frontiers Media SA
- Published
- 2022-01-10
- Volume
- 12
- Pages
- 814770-814770
- ISSN
- 1664-2392 (ISSN-L)
- OpenAlex
- W4205548172
- Cited by
- 92
- References
- 19
- FWCI
- 4.83
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Gut Microbial Signatures for Glycemic Responses of GLP-1 Receptor Agonists in Type 2 Diabetic Patients: A Pilot Study. https://app.cochat.ai/papers/10.3389/fendo.2021.814770
- The paper
- Tsai, C.-Y., Lu, H.-C., Chou, Y.-H., Liu, P.-Y., Chen, H.-Y., Huang, M.-C., Lin, C.-H., & Tsai, C.-N. (2022). Gut Microbial Signatures for Glycemic Responses of GLP-1 Receptor Agonists in Type 2 Diabetic Patients: A Pilot Study. Frontiers in Endocrinology. https://doi.org/10.3389/fendo.2021.814770
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.